First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies
OmniAb, Inc. announces the launch of its new OmniUltra platform, the industry’s first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego.
Health Technology Insights: Dilon Technologies Gets FDA Approval for MarginProbe 2 Launch
OmniUltra is a versatile in vivo discovery platform that extends beyond traditional antibody modalities into the peptide space, enabling multiple therapeutic applications. It generates naturally optimized human immune antibody repertoires featuring cow-inspired ultralong CDRH3 domains, unlocking novel binding modes and access to challenging targets. OmniUltra also enables the isolation of picobodies, the smallest known natural antibody-derived binding domain (4–6 kDa), which are approximately one-third the size of a nanobody. OmniUltra is designed to deliver pre-optimized specificity, affinity, and structural stability, streamlining hit-to-lead identification. By generating both antibodies and picobodies, it is ideal for applications such as bispecifics, multispecifics, CAR-T, radioligands and stand-alone peptide therapeutics.
Health Technology Insights: Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
“We are incredibly proud and excited to launch OmniUltra, our newest transgenic chicken platform and a pioneering advancement in antibody and peptide discovery. Building upon our unrivaled expertise in utilizing chicken hosts to develop novel antibodies, OmniUltra allows us to produce cow-inspired ultralong CDRH3s for partners to generate highly unique antibodies and novel peptide therapeutics,” said Matt Foehr, Chief Executive Officer of OmniAb. “This technology opens unprecedented opportunities for OmniAb, expanding our reach into new markets and applications while reinforcing our leadership in next-generation drug discovery innovation. The rigorous validation work we’ve completed demonstrates the broad applicability of OmniUltra, positioning us for a highly impactful launch with strong industry engagement, which already has begun with several of our partners.”
The OmniUltra launch to industry leaders and prospective customers attending AET features two podium presentations, including one delivered earlier today titled “OmniUltra: A New in vivo Platform for Discovery of Novel Mini-Proteins and Structured Peptides.” The Company will be highlighting the OmniUltra platform in a second presentation titled “OmniUltra: Leveraging Evolutionary distance for the Discovery of Ultralong CDRH3 Antibodies with Broad Epitope Coverage” on December 16th at 12:35 p.m. Pacific time.
In addition, OmniAb will have two poster presentations at AET, titled “Empowering the efficient discovery of ultralong CDRH3 antibodies with high-throughput xPloration workflows” and “Development of OmniUltra: A transgenic chicken platform for the generation of ultralong CDRH3 antibodies, mini-proteins and structured peptides for human therapeutics.”
“Therapeutic peptides offer transformative clinical benefits across a broad spectrum of indications, from metabolic disorders to oncology. Their high target selectivity, structural adaptability and potentially low immunogenicity provide unique advantages over conventional small molecules and antibody-based drugs,” said Yasmina Abdiche, Ph.D., Senior Vice President, Exploratory Research of OmniAb. “OmniUltra’s proprietary in vivo platform generates structured peptides on a validated scaffold, inspired by the ultralong CDRH3 architecture found in bovine antibodies. By leveraging the evolutionary distance of the chicken host, we harness the power of its immune system to expand the recognition of human targets. With this technology we can also isolate ultralong CDRH3-derived peptides and chemically synthesize them, unlocking a new paradigm in peptide therapeutic innovation.”
OmniAb is showcasing OmniUltra and its entire technology stack at the 2025 Antibody Engineering & Therapeutics Conference at booth #300 at the Marriott Marquis San Diego Marina, December 15-18.
Health Technology Insights: Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
